EP0331630A1 - Use of IGF-I for the manufacture of a preparation for treating and preventing secondary effects of hyperinsulinemia in diabetics treated with insulin - Google Patents
Use of IGF-I for the manufacture of a preparation for treating and preventing secondary effects of hyperinsulinemia in diabetics treated with insulin Download PDFInfo
- Publication number
- EP0331630A1 EP0331630A1 EP89810074A EP89810074A EP0331630A1 EP 0331630 A1 EP0331630 A1 EP 0331630A1 EP 89810074 A EP89810074 A EP 89810074A EP 89810074 A EP89810074 A EP 89810074A EP 0331630 A1 EP0331630 A1 EP 0331630A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- igf
- insulin
- treating
- processed
- hyperinsulinemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010060378 Hyperinsulinaemia Diseases 0.000 title claims abstract description 14
- 230000003451 hyperinsulinaemic effect Effects 0.000 title claims abstract description 14
- 201000008980 hyperinsulinism Diseases 0.000 title claims abstract description 14
- 230000009291 secondary effect Effects 0.000 title claims abstract description 14
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title claims description 118
- 102000004877 Insulin Human genes 0.000 title claims description 59
- 108090001061 Insulin Proteins 0.000 title claims description 59
- 229940125396 insulin Drugs 0.000 title claims description 59
- 238000004519 manufacturing process Methods 0.000 title claims description 10
- 238000002360 preparation method Methods 0.000 title claims description 4
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 title abstract description 5
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 title abstract description 5
- 238000000034 method Methods 0.000 claims abstract description 17
- 238000001802 infusion Methods 0.000 claims description 36
- 210000004369 blood Anatomy 0.000 claims description 21
- 239000008280 blood Substances 0.000 claims description 21
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 20
- 239000008103 glucose Substances 0.000 claims description 20
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 16
- 238000007920 subcutaneous administration Methods 0.000 claims description 12
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 10
- 230000000694 effects Effects 0.000 claims description 6
- 238000001990 intravenous administration Methods 0.000 claims description 6
- 206010012601 diabetes mellitus Diseases 0.000 claims description 5
- 238000007796 conventional method Methods 0.000 claims description 4
- 238000007918 intramuscular administration Methods 0.000 claims description 3
- 230000002195 synergetic effect Effects 0.000 claims description 3
- 230000003178 anti-diabetic effect Effects 0.000 claims description 2
- 239000003472 antidiabetic agent Substances 0.000 claims description 2
- 102100037852 Insulin-like growth factor I Human genes 0.000 abstract description 78
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 4
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 76
- 210000002966 serum Anatomy 0.000 description 22
- 230000037396 body weight Effects 0.000 description 13
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 12
- 108010075254 C-Peptide Proteins 0.000 description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 241000282414 Homo sapiens Species 0.000 description 7
- 208000013016 Hypoglycemia Diseases 0.000 description 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 6
- 238000003556 assay Methods 0.000 description 5
- 230000002218 hypoglycaemic effect Effects 0.000 description 5
- 230000002093 peripheral effect Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 208000008589 Obesity Diseases 0.000 description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000004190 glucose uptake Effects 0.000 description 4
- 230000003914 insulin secretion Effects 0.000 description 4
- 235000020824 obesity Nutrition 0.000 description 4
- 206010022489 Insulin Resistance Diseases 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000003978 infusion fluid Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 102000018997 Growth Hormone Human genes 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- 102000003746 Insulin Receptor Human genes 0.000 description 2
- 108010001127 Insulin Receptor Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 1
- 101100097985 Caenorhabditis elegans mars-1 gene Proteins 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101150088952 IGF1 gene Proteins 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000020934 caloric restriction Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000014101 glucose homeostasis Effects 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000022001 negative regulation of insulin secretion Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000011885 synergistic combination Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Definitions
- the invention concerns a method for treating and preventing secondary effects of hyperinsulinemia by application of insulin-like growth factor I (IGF I), and pharmaceutical compositions comprising IGF I which are useful for this purpose.
- IGF I insulin-like growth factor I
- Insulin regulates blood glucose by
- Insulin exerts these effects by interacting with the insulin receptor present on most cells.
- the sensitivity to insulin is a function of the number of insulin receptors of individual cells. This number is decreased or "downregulated" by insulin, i.e. high concentrations of insulin secondarily lead to relative insulin resistance.
- Conditions characterized by an excessive endogenous insulin secretion are obesity, type 2 diabetes, hyperlipidemia type IV of Fredricksen.
- type 1 diabetes juvenile diabetes mellitus, insulin dependent
- insulin resistance is the consequence of the peripheral administration of insulin so that the glucose homeostatic function of the liver is impaired and peripheral glucose uptake excessive.
- the treatment of obesity, type 2 diabetes (non-insulin dependent) and hyperlipidemia consists primarly of dietary measures, i.e. caloric restriction.
- IGF I Insulin-like growth factor I
- IGF I insulin secretion is decreased and that IGF I helps to maintain glucose homeostasis with considerably less insulin thus overcoming the drawbacks of hyperinsulinemia.
- IGF I leads to hypoglycemia by increasing glucose uptake primarily of muscle. It is conceivable that IGF I infusions may also facilitate glucose uptake by muscle and this effect is dose related. The second, so far unknown effect has to do with insulin degradation.
- Object of the invention is to prevent the secondary effects of administered insulin in diabetics and to minimize the effets of excessive endogenous insulin in obesity, typ 2 diabetes and hyperlipidemia.
- Further object of the invention is to provide pharmaceutical compositions containing IGF I in dosage unit form and in such amounts as to achieve said beneficial effects.
- the invention concerns a method for treating and preventing secondary effects of hyperinsulinemia in diabetics treated with insulin, characterized in that an effective amount of IGF I and a lower than normal amount of insulin is administered.
- the invention also concerns a method for treating type 2 diabetics, obese subjects and subjects with hyperlipidemia characterized in that an effective amount of IGF I alone is administered.
- IGF I recombinant human IGF I (rhIGF 1), prepared e.g. according to EP 123 228.
- Any type of insulin may be used, such as from pork or bovine, or preferively human recombinant insulin.
- An effective amount is defined as an amount having a therapeutic effect on the envisioned conditions to be treated.
- IGF I is administered intravenously, subcutaneously or intramuscularly in doses between about 24 ⁇ g/kg/day up to about 720 ⁇ g/kg/day, or if given continuously in doses of about 1 ⁇ g/kg/h up to about 30 ⁇ g/kg/h, either by two daily injections or by subcutaneous infusions, e.g. via a minipump, respectively.
- a total of about 3000 ⁇ g/kg equivalent to a total daily dose of 500 ⁇ g/kg may be administered.
- IGF I is administered together with insulin the latter is used in lower amounts than if used alone, down to amounts which by themselves have little effect on blood glucose, i.e. in amounts of between about 0.1 IU/kg/24 h up to about 0.5 IU/kg/24 h.
- the dosage has of course to be adjusted to the patient's specific disease, the route of administration, the individual weight and general condition of the patient to be treated and is finally dependent on the judgement of the physician.
- Caution should be taken that blood glucose is monitored and hypoglycemia prevented.
- compositions for preventing secondary effects in diabetics comprise an effective amount of IGF I, i.e. an amount of from about 20 mg to about 300 mg.
- IGF I and insulin Due to the synergistic effects of the combination of IGF I and insulin, the latter is present in such combination in an amount of from 0.2 mg up to 10.0 mg.
- the pharmaceutical preparation contains an effective amount of the active ingredient(s) together or in admixture with inorganic or organic, solid or liquid, pharmaceutically acceptable carriers which are suitable preferably for parenteral administration.
- the active compound of the present invention is preferably used in the form of pharmaceutical preparations such as infusion solutions for parenteral, for example subcutaneous, intramuscular or intravenous, administration.
- Such solutions are preferably isotonic aqueous solutions or suspensions which can be prepared before use, for example from lyophilised preparations which contain the active ingredient alone or together with a pharmaceutically acceptable carrier.
- the pharmaceutical preparations may be sterilised and/or contain adjuncts, for example preservatives, stabilisers, wetting agents and/or emulsifiers, solubilisers, salts for regulating the osmotic pressure and/or buffers.
- the present pharmaceutical preparations which may, if desired, contain further pharmacologically valuable substances, are produced in a manner known per se , for example by means of conventional dissolving or lyophilising processes, and contain from approximately 0.1 % to 100 %, especially from approximately 1 % to approximately 50 %, and in the case of lyophilisates up to 100 %, of the active ingredient(s).
- IGF I and insulin can be in a fixed form, i.e. predetermined amounts of both active ingredients are combined in one dosage unit form, or in separated dosage unit forms. The latter form allows to adjust the dose for each compound more individually.
- the invention concerns also a synergistic antidiabetic pharmaceutical combination of IGF I and insulin, and a method for the manufacture of a pharmaceutical preparation for treating and preventing secondary effects of hyperinsulinemia in diabetics treated with insulin, characterized in that IGF I and a lower than normal amount of insulin are pharmaceutically processed according to conventional methods.
- the invention concerns further the use of the pharmaceutical combinations for the prevention of secondary effects of hyperinsulinemia in diabetics treated with insulin.
- the invention concerns further a method for the manufacture of a pharmaceutical preparation for treating type 2 diabetics, obese subjects or subjects with hyperlipidemia, characterized in that IGF I is pharmaceutically processed according to conventional methods.
- the invention concerns also the use of IGF I alone for the manufacture of a pharmaceutical preparation for the prevention of secondary effects in type 2 diabetics, obese subjects and subjects with hyperlipidemia which may contain instructions for its use, and the use of IGF I for the manufacture of a synergistic combination comprising IGF I and insulin.
- the invention concerns also a pharmaceutical preparation or pack comprising IGF I or a combination of IGI and insulin, and which may include instructions for use.
- IGF I recombinant human IGF I
- rhIGF I recombinant human IGF I
- Dry ampoules containing 50 mg or 300 mg of IGF I ampoules of 5 ml or 50 ml, respectively, volume are filled with 5 ml or 30 ml, respectively, of sterile filtered 10 % (w/v) aqueous solution of IGF I and lyophilized.
- the infusion solution is prepared by adding the respective volume (5 or 30 ml) of sterile water, physiological saline, or 0.1 M acetic acid.
- the therapeutic combination contains the desired number of ampoules necessary for one course of treatment, e.g. for 6 days, and optional instructions for application which stipulate the time during which the medicament should be infused.
- Dry ampoules containing 50 mg or 300 mg of IGF I ampoules of 5 ml or 50 ml, respectively, volume are filled with 5 ml or 30 ml, respectively, of sterile filtered 10 % (w/v) aqueous solution of IGF I.
- Insulin preferably human recombinant insulin, is added in an amount of 0.2 mg or 10 mg, and the vials are lyophilized.
- the infusion solution is prepared by adding the respective volume (5 or 30 ml) of sterile water, physiological saline, or 0.1 M acetic acid.
- the therapeutic combination contains the desired number of ampoules necessary for one course of treatment, e.g. for 6 days, and optional instructions for application which stipulate the time during which the medicament should be infused.
- Baseline values were obtained during an initial control period after which IGF I was administered by continuous s.c.infusion during six days. This method and duration of administration was selected in order to reach constant serum levels of IGF I. The study was concluded with a second control period. Food intake was strictly controlled during the whole study and consisted of 2500 kcal per day (25 % protein, i.e. 1.9 g protein per kilogram body weight, 20 % fat and 55 % carbohydrate).
- IGF I insulin growth factor
- IGF I was infused at the same dose as in subject 1 (20.0 ⁇ g per kilogram body weight and hour) during a total of six days. The total amount of IGF I infused was 167 mg.
- a miniaturized insulin-infusion device (MRS 1 Infusor R / Disetronic AG, Burgdorf, Switzerland) was used. IGF I was dissolved in 0.1 M acetic acid. 25 ⁇ l per hour were infused. The infusor cartridge containing the IGF I was refilled after 3 days. A micro-catheter was placed under the skin of the abdomen. It was changed after 3 days and placed at a location distant from the first one.
- Serum levels of insulin and C-peptide were measured every morning in fasting serum samples and in subject 2 also during the sixth night of IGF I infusion as well as during a night several weeks after the infusion.
- Venous Blood was obtained every morning between 6 and 7 a.m. It was immediately placed on ice and centrifuged one hour later. Serum or plasma was stored in 1 ml portions at -20°C. All assays were done in samples that had not been thawed before.
- Total IGF I and free IGF I were measured by radioimmunoassay as described earlier (6, 7). Blood glucose was determined by YSI 23A glucose analyzer. Commercially available kits were used to determine growth hormone (hGH-RIA-Kit, Medipro, Teufen, Switzerland), insulin (RIA-GNOST Insulin, Behringwerke AG, Marburg, Germany) and C-peptide (RIA kit for human C-peptide, Medigenix, Fleurus, Belgium). All other analyses were kindly performed in the Department of Clinical Chemistry of the University Hospital of Switzerland.
- IGF-I Dose finding in subject 1 (Fig. 1) After three control days (without any hormone) the IGF I infusion was started at 6.30 a.m. at a rate of 32.0 ⁇ g per kilogram body weight per hour. Blood glucose was 4.4 mmol per liter, the serum level of total IGF I 120 ng per milliliter and that of free IGF I 20 ng per milliliter. 13.5 hours later, after the infusion of a total of 28.1 mg of IGF I and 8 hours after the last meal, blood glucose had fallen to 2.6 mmol per liter without any clinical signs of hypoglycemia.
- Blood glucose was monitored daily after overnight fasting (at least 12 hours) and remained between 3.7 to 4.4 mmol per liter throughout the study.
- blood glucose levels measured every hour during one night of IGF I infusion were between 3.6 and 4.4 mmol per liter.
- Serum levels of triglycerides of subject 2 were determined by a routine enzymatic colour test (GPO-PAP) with an Hitachi 737 Multi Analyser of blood samples drawn in the morning after an over-night fast.
- Table 1 Day Triglyceride Level in mmol/l Subject 2 Subject 3 Subject 4 Subject 5 -3 1.65 1.59 0.70 - -2 1.37 - - - -1 1.24 1.54 0.76 1.24 1 1.50 0.98 0.75 1.29 2@ 1.12 1.01 0.54 0.61 3@ 0.77 0.63 0.63 0.92 4@ 0.78 0.99 0.51 0.81 5@ 0.74 0.69 0.60 0.48 6@ 0.74 0.73 0.69 0.70 7 1.06 1.23 0.52 0.85 8 1.16 1.21 0.70 0.79 9 1.24 0.93 0.57 0.72 11 1.93 1.31 0.58 0.66
- IGF I levels rose and reached levels of 700 ng per milliliter after 13 to 14 hours. Peak levels in the two subjects were 980 and 920 ng per milliliter, respectively. When the infusion was stopped IGF I levels fell in the normal range within one day.
- Free IGF I levels during the control days were between 15 and 20 ng per milliliter and between 50 and 80 ng per milliliter during continuous IGF I infusion.
- Subcutaneous infusions of IGF I in a dose of 20.0 ⁇ g per kilogram body weight and hour to healthy adults are safe, do not influence general well-being, blood pressure, pulse rate and body temperature and do not lead to hypoglycemia.
- Under the IGF I infusion serum levels of triglyceride are markedly reduced. Morning fasting serum levels of insulin remain in the normal range whereas C-peptide levels are below 50 pmol/l (Fig. 3).
- IGF I appears to make the organism more sensitive to insulin and from this point of view becomes a potentially very exciting therapeutic tool for the treatment of insulin resistance, such as in type 2 diabetes, obesity, hyperlipidemia, and, of course, also type 1 diabetes.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
- The invention concerns a method for treating and preventing secondary effects of hyperinsulinemia by application of insulin-like growth factor I (IGF I), and pharmaceutical compositions comprising IGF I which are useful for this purpose.
- Insulin regulates blood glucose by
- a) decreasing glucose outflow from the liver and
- b) increasing glucose uptake in peripheral tissues, e.g. muscles and adipose tissues.
- Insulin exerts these effects by interacting with the insulin receptor present on most cells. The sensitivity to insulin is a function of the number of insulin receptors of individual cells. This number is decreased or "downregulated" by insulin, i.e. high concentrations of insulin secondarily lead to relative insulin resistance. Conditions characterized by an excessive endogenous insulin secretion are obesity,
type 2 diabetes, hyperlipidemia type IV of Fredricksen. Intype 1 diabetes (juvenile diabetes mellitus, insulin dependent) insulin resistance is the consequence of the peripheral administration of insulin so that the glucose homeostatic function of the liver is impaired and peripheral glucose uptake excessive. The treatment of obesity,type 2 diabetes (non-insulin dependent) and hyperlipidemia consists primarly of dietary measures, i.e. caloric restriction. Patient compliance is notoriously bad and there is a need for new and better therapeutic measures. In insulin treatedtype 1 diabetes, hyperinsulinemia results from the fact that insulin is delivered s.c. rather than intraportally so that the delivered insulin reaches peripheral tissues first rather than after passage through the liver. There is a need to overcome the drawbacks of excessive insulin secretion and hyperinsulinemia. - Insulin-like growth factor I (IGF I) has been shown to lower blood glucose in man after intravenous bolus injection (1). Growth-promoting actions of IGF I have been documented in several metabolic conditions which have low IGF I levels in common, e.g. hypophysectomized rats (2) (5), diabetic rats (3) and Snell dwarf mice (4).
- It has now been found that prolonged infusions of IGF I inhibit growth hormone secretion. In addition, blood glucose and peripheral levels of insulin remained constant but the levels of the C-peptide fell markedly indicating that endogenous insulin secretion was reduced. During IGF I infusion triglyceride, cholesterol and LDL-cholesterol tended to decrease while HDL-cholesterol increased. These findings show that during IGF I infusions insulin secretion is decreased and that IGF I helps to maintain glucose homeostasis with considerably less insulin thus overcoming the drawbacks of hyperinsulinemia. There are at least two mechanisms of action of IGF I: As shown in the bolus experiments, IGF I leads to hypoglycemia by increasing glucose uptake primarily of muscle. It is conceivable that IGF I infusions may also facilitate glucose uptake by muscle and this effect is dose related. The second, so far unknown effect has to do with insulin degradation.
- So far there exists no report on the inhibition of insulin secretion during administration of IGF I. It is foreseen that the administration of IGF I leads to a diminished need of insulin thereby preventing the secondary effects of hyperinsulinemia.
- Object of the invention is to prevent the secondary effects of administered insulin in diabetics and to minimize the effets of excessive endogenous insulin in obesity,
typ 2 diabetes and hyperlipidemia. - Further object of the invention is to provide pharmaceutical compositions containing IGF I in dosage unit form and in such amounts as to achieve said beneficial effects.
- The invention concerns a method for treating and preventing secondary effects of hyperinsulinemia in diabetics treated with insulin, characterized in that an effective amount of IGF I and a lower than normal amount of insulin is administered.
- The invention also concerns a method for treating
type 2 diabetics, obese subjects and subjects with hyperlipidemia characterized in that an effective amount of IGF I alone is administered. - Any source of IGF I can be used whether from natural sources or synthetically produced. Preferred is recombinant human IGF I (rhIGF 1), prepared e.g. according to EP 123 228.
- Any type of insulin may be used, such as from pork or bovine, or preferably human recombinant insulin.
- An effective amount is defined as an amount having a therapeutic effect on the envisioned conditions to be treated.
- IGF I is administered intravenously, subcutaneously or intramuscularly in doses between about 24 µg/kg/day up to about 720 µg/kg/day, or if given continuously in doses of about 1 µg/kg/h up to about 30 µg/kg/h, either by two daily injections or by subcutaneous infusions, e.g. via a minipump, respectively. During 6 days a total of about 3000 µg/kg equivalent to a total daily dose of 500 µg/kg may be administered.
- If IGF I is administered together with insulin the latter is used in lower amounts than if used alone, down to amounts which by themselves have little effect on blood glucose, i.e. in amounts of between about 0.1 IU/kg/24 h up to about 0.5 IU/kg/24 h.
- The dosage has of course to be adjusted to the patient's specific disease, the route of administration, the individual weight and general condition of the patient to be treated and is finally dependent on the judgement of the physician. Caution should be taken that blood glucose is monitored and hypoglycemia prevented.
- Pharmaceutical compositions for preventing secondary effects in diabetics comprise an effective amount of IGF I, i.e. an amount of from about 20 mg to about 300 mg.
- Due to the synergistic effects of the combination of IGF I and insulin, the latter is present in such combination in an amount of from 0.2 mg up to 10.0 mg.
- In general the pharmaceutical preparation contains an effective amount of the active ingredient(s) together or in admixture with inorganic or organic, solid or liquid, pharmaceutically acceptable carriers which are suitable preferably for parenteral administration.
- The active compound of the present invention, alone or in combination with insulin, is preferably used in the form of pharmaceutical preparations such as infusion solutions for parenteral, for example subcutaneous, intramuscular or intravenous, administration. Such solutions are preferably isotonic aqueous solutions or suspensions which can be prepared before use, for example from lyophilised preparations which contain the active ingredient alone or together with a pharmaceutically acceptable carrier. The pharmaceutical preparations may be sterilised and/or contain adjuncts, for example preservatives, stabilisers, wetting agents and/or emulsifiers, solubilisers, salts for regulating the osmotic pressure and/or buffers. The present pharmaceutical preparations, which may, if desired, contain further pharmacologically valuable substances, are produced in a manner known per se, for example by means of conventional dissolving or lyophilising processes, and contain from approximately 0.1 % to 100 %, especially from approximately 1 % to approximately 50 %, and in the case of lyophilisates up to 100 %, of the active ingredient(s).
- If a combination of IGF I and insulin is envisaged, it can be in a fixed form, i.e. predetermined amounts of both active ingredients are combined in one dosage unit form, or in separated dosage unit forms. The latter form allows to adjust the dose for each compound more individually.
- The invention concerns also a synergistic antidiabetic pharmaceutical combination of IGF I and insulin, and a method for the manufacture of a pharmaceutical preparation for treating and preventing secondary effects of hyperinsulinemia in diabetics treated with insulin, characterized in that IGF I and a lower than normal amount of insulin are pharmaceutically processed according to conventional methods.
- The invention concerns further the use of the pharmaceutical combinations for the prevention of secondary effects of hyperinsulinemia in diabetics treated with insulin.
- The invention concerns further a method for the manufacture of a pharmaceutical preparation for treating
type 2 diabetics, obese subjects or subjects with hyperlipidemia, characterized in that IGF I is pharmaceutically processed according to conventional methods. - The invention concerns also the use of IGF I alone for the manufacture of a pharmaceutical preparation for the prevention of secondary effects in
type 2 diabetics, obese subjects and subjects with hyperlipidemia which may contain instructions for its use, and the use of IGF I for the manufacture of a synergistic combination comprising IGF I and insulin. - The invention concerns also a pharmaceutical preparation or pack comprising IGF I or a combination of IGI and insulin, and which may include instructions for use.
- Following are examples of pharmaceutical preparations according to the invention which, however, should not be construed as a limitation thereof. In the Examples the term IGF I, it not otherwise specified, relates to recombinant human IGF I (rhIGF I), which was prepared according to EP 123 228. It has been characterized chemically and biologically and found to be identical to highly purified extracted human IGF 1. The same material had been used in a previous study in man (1).
- Dry ampoules containing 50 mg or 300 mg of IGF I: ampoules of 5 ml or 50 ml, respectively, volume are filled with 5 ml or 30 ml, respectively, of sterile filtered 10 % (w/v) aqueous solution of IGF I and lyophilized. The infusion solution is prepared by adding the respective volume (5 or 30 ml) of sterile water, physiological saline, or 0.1 M acetic acid.
- The therapeutic combination contains the desired number of ampoules necessary for one course of treatment, e.g. for 6 days, and optional instructions for application which stipulate the time during which the medicament should be infused.
- Dry ampoules containing 50 mg or 300 mg of IGF I: ampoules of 5 ml or 50 ml, respectively, volume are filled with 5 ml or 30 ml, respectively, of sterile filtered 10 % (w/v) aqueous solution of IGF I. Insulin, preferably human recombinant insulin, is added in an amount of 0.2 mg or 10 mg, and the vials are lyophilized. The infusion solution is prepared by adding the respective volume (5 or 30 ml) of sterile water, physiological saline, or 0.1 M acetic acid.
- The therapeutic combination contains the desired number of ampoules necessary for one course of treatment, e.g. for 6 days, and optional instructions for application which stipulate the time during which the medicament should be infused.
- Two males (age/body weight/height):1.: 38/65/172; 2.: 34/61/1.72) served as normal subjects in this clinical trial. Their body weight was ideal and they had no clinical evidence of illness and did not take any medication. Routine hematology, blood chemistry and endocrine parameters were within normal limits.
- Baseline values were obtained during an initial control period after which IGF I was administered by continuous s.c.infusion during six days. This method and duration of administration was selected in order to reach constant serum levels of IGF I. The study was concluded with a second control period. Food intake was strictly controlled during the whole study and consisted of 2500 kcal per day (25 % protein, i.e. 1.9 g protein per kilogram body weight, 20 % fat and 55 % carbohydrate).
- Both control periods lasted for three days. On the first day of treatment, IGF I was initially infused at an arbitrary dose of 32.0 µg per kilogram body weight and hour. This dose of IGF I caused hypoglycemia (see result section). 20.0 µg per kilogram body weight and hour during the next five days were found to be safe and blood glucose remained normal. The total amount of IGF I infused during six days was 184 mg.
- Both control periods were five days. IGF I was infused at the same dose as in subject 1 (20.0 µg per kilogram body weight and hour) during a total of six days. The total amount of IGF I infused was 167 mg.
- A miniaturized insulin-infusion device (
MRS 1 InfusorR/ Disetronic AG, Burgdorf, Switzerland) was used. IGF I was dissolved in 0.1 M acetic acid. 25 µl per hour were infused. The infusor cartridge containing the IGF I was refilled after 3 days. A micro-catheter was placed under the skin of the abdomen. It was changed after 3 days and placed at a location distant from the first one. - Serum levels of insulin and C-peptide were measured every morning in fasting serum samples and in
subject 2 also during the sixth night of IGF I infusion as well as during a night several weeks after the infusion. - Venous Blood was obtained every morning between 6 and 7 a.m. It was immediately placed on ice and centrifuged one hour later. Serum or plasma was stored in 1 ml portions at -20°C. All assays were done in samples that had not been thawed before.
- 24 Hours-Urine collections were obtained throughout the study (6 a.m. to 6 a.m.). Several aliquots were stored at -20°C.
- Total IGF I and free IGF I were measured by radioimmunoassay as described earlier (6, 7). Blood glucose was determined by YSI 23A glucose analyzer. Commercially available kits were used to determine growth hormone (hGH-RIA-Kit, Medipro, Teufen, Switzerland), insulin (RIA-GNOST Insulin, Behringwerke AG, Marburg, Germany) and C-peptide (RIA kit for human C-peptide, Medigenix, Fleurus, Belgium). All other analyses were kindly performed in the Department of Clinical Chemistry of the University Hospital of Zürich.
- IGF-I Dose finding in subject 1 (Fig. 1) After three control days (without any hormone) the IGF I infusion was started at 6.30 a.m. at a rate of 32.0 µg per kilogram body weight per hour. Blood glucose was 4.4 mmol per liter, the serum level of total IGF I 120 ng per milliliter and that of free IGF I 20 ng per milliliter. 13.5 hours later, after the infusion of a total of 28.1 mg of IGF I and 8 hours after the last meal, blood glucose had fallen to 2.6 mmol per liter without any clinical signs of hypoglycemia. By that time the serum level of total IGF I had reached 683 ng per milliliter, and the serum level of free IGF I was 123 ng per milliliter. The infusion was stopped overnight and started again on the next morning at 6.30 a.m. at a rate of 20.0 µg per kilogram body weight and hour. This dose was kept constant during the subsequent 5 days in
subject 1 and was also used during the whole six day infusion period insubject 2. - Apart from the hypoglycemic episode in
subject 1 on the first day of the IGF I infusion, no other such event was recorded. Both subjects felt normal throughout the study. Blood pressure, pulse rate, body temperature and body weight remained stable. - Blood glucose was monitored daily after overnight fasting (at least 12 hours) and remained between 3.7 to 4.4 mmol per liter throughout the study. In
subject 2 blood glucose levels measured every hour during one night of IGF I infusion were between 3.6 and 4.4 mmol per liter. - Serum levels of triglycerides of
subject 2 were determined by a routine enzymatic colour test (GPO-PAP) with an Hitachi 737 Multi Analyser of blood samples drawn in the morning after an over-night fast. - In a similar manner three further subjects were treated with 20 µg/kg/h of IGF I and the serum levels of triglycerides determined.
- The results are compiled in Table 1.
Table 1 Day Triglyceride Level in mmol/ l Subject 2 Subject 3Subject 4Subject 5 -3 1.65 1.59 0.70 - -2 1.37 - - - -1 1.24 1.54 0.76 1.24 1 1.50 0.98 0.75 1.29 2@ 1.12 1.01 0.54 0.61 3@ 0.77 0.63 0.63 0.92 4@ 0.78 0.99 0.51 0.81 5@ 0.74 0.69 0.60 0.48 6@ 0.74 0.73 0.69 0.70 7 1.06 1.23 0.52 0.85 8 1.16 1.21 0.70 0.79 9 1.24 0.93 0.57 0.72 11 1.93 1.31 0.58 0.66 - Continuous infusion from
day 1 today 6. The value ofday 1 was taken before the infusion started. - Within two to four hours after starting the infusion, IGF I levels rose and reached levels of 700 ng per milliliter after 13 to 14 hours. Peak levels in the two subjects were 980 and 920 ng per milliliter, respectively. When the infusion was stopped IGF I levels fell in the normal range within one day.
- Free IGF I levels during the control days were between 15 and 20 ng per milliliter and between 50 and 80 ng per milliliter during continuous IGF I infusion.
- All fasting insulin values before, during and after the infusion were between 17 and 77 pmol per liter. Similar values were found in subject 2 during the sixth night and five weeks after the infusion in blood samples taken every hour (51 to 77 pmol per liter).
- Fasting serum levels of C-peptide drawn every morning before and after the infusion were 450±80 pmol per liter, whereas during the infusion period all but two values (95 and 69 pmol per liter, respectively) were below the detection limit of the assay (50 pmol per liter) (Fig. 3). Serum levels of C-peptide were also measured during the sixth night of the infusion in subject 2: all but one value at 10 p.m. (98 pmol per liter) were below 50 pmol per liter. During a control night five weeks after the infusion C-peptide levels were 650±440 pmol per liter (Fig. 4).
- Subcutaneous infusions of IGF I in a dose of 20.0 µg per kilogram body weight and hour to healthy adults are safe, do not influence general well-being, blood pressure, pulse rate and body temperature and do not lead to hypoglycemia. Under the IGF I infusion serum levels of triglyceride are markedly reduced. Morning fasting serum levels of insulin remain in the normal range whereas C-peptide levels are below 50 pmol/l (Fig. 3).
- Normal insulin levels in the presence of decreased C-peptide levels, as observed in the present study, indicates a decrease of insulin degradation and consecutively a prolongation of its half-life.
- IGF I appears to make the organism more sensitive to insulin and from this point of view becomes a potentially very exciting therapeutic tool for the treatment of insulin resistance, such as in
type 2 diabetes, obesity, hyperlipidemia, and, of course, also type 1 diabetes. -
- Fig. 1: Blood glucose and free IGF I serum levels on the first day of continuous s.c.infusion of recombinant IGF I at a rate of 32.0 µg per kilogram body weight and hour in
subject 1. The infusion was begun at 6.30 a.m. and stopped at 8.00 p.m. when blood glucose had fallen to 2.6 mmol per liter. Serum levels of free IGF I by that time had increased from basel values of 20 ng per milliliter to 123 ng per milliliter. "M" indicates the time of the meals. - Fig. 2: Serum levels of total IGF I in two subjects before, during and after six days under constant s.c.infusion of recombinant IGF I in a dose of 20.0 µg per kilogram body weight and hour.
- Fig. 3: Serum levels of C-peptide and insulin in two subjects before, during and after six days under constant s.c. infusion of recombinant IGF I in a dose of 20 µg per kilogram body weight per hour. The dotted line represents the detection limit of the assay.
- Fig. 4: C-peptide levels in subject 2 from 10 p.m. to 6 a.m. during the sixth night of IGF I infusion (Δ) and during a control night (·) five weeks later. Blood glucose and insulin were within normal limits on both occasions. The dotted line represents the detection limit of the assay.
-
- 1. Guler HP, Zapf J, Froesch ER. Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults. N Engl J Med 1987; 317:137-40.
- 2. Guler HP, Zenobi P, Zapf J, et al. IGF I and II and recombinant human IGF I are hypoglycemic in the rat, mini-pig, and men. Endocrinology 1986; 118:Suppl:129, abstract.
- 3. Scheiwiller E, Guler HP, Merryweather J, Scandella C, Maerki W, Zapf J, Froesch ER. Growth restoration of insulin-deficient diabetic rats by recombinant human insulin-like growth factor I. Nature 1986; 323:169-71.
- 4. van BUUl-Offers S, Ueda I, Van den Brandle JL. Biosynthetic somatomedin C (SM-C/IGF-1) increases the length and weight of Snell dwarf mice. Pediatr Res 1986; 20:825-7.
- 5. Guler HP, Zapf J, Froesch ER. S.c.infusion of recombinant human insulin-like growth factor I (rhIGF I) stimulates growth of hypophysectomized rats continuously during 18 days. Proceedings of the lst European Congress of Endocrinology, Copenhagen 1987; 103, abstract 12-390.
- 6. Zapf J, Walter H, Froesch ER. Radioimmunological determination of insulin-like growth factors I and II in normal subjects and in patients with growth disorders and extrapancreatic tumor hypoglycemia. J Clin Invest 1981; 68:1321-30.
- 7. Zapf J, Hauri C, Waldvogel M, Froesch ER. Acute metabolic effects and half-lives of intravenously administered insulin-like growth factors I and II in normal and hypophysectomized rats. J. Clin Invest 1986; 77:1768-75.
Claims (21)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT89810074T ATE86497T1 (en) | 1988-02-05 | 1989-01-26 | USE OF IGF-I IN THE MANUFACTURE OF A PREPARATION FOR THE TREATMENT AND PREVENTION OF SIDE EFFECTS OF HYPERINSULINEMIA IN DIABETICS TREATED WITH INSULIN. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP88810072 | 1988-02-05 | ||
EP88810072 | 1988-02-05 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0331630A1 true EP0331630A1 (en) | 1989-09-06 |
EP0331630B1 EP0331630B1 (en) | 1993-03-10 |
Family
ID=8200571
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP89810074A Expired - Lifetime EP0331630B1 (en) | 1988-02-05 | 1989-01-26 | Use of igf-i for the manufacture of a preparation for treating and preventing secondary effects of hyperinsulinemia in diabetics treated with insulin |
Country Status (13)
Country | Link |
---|---|
US (1) | US4988675A (en) |
EP (1) | EP0331630B1 (en) |
JP (1) | JP2831017B2 (en) |
KR (1) | KR0131087B1 (en) |
AU (1) | AU624595B2 (en) |
CA (1) | CA1336815C (en) |
DE (1) | DE68905205T2 (en) |
DK (1) | DK169233B1 (en) |
IE (1) | IE63163B1 (en) |
IL (1) | IL89166A0 (en) |
NZ (1) | NZ227857A (en) |
PH (1) | PH26085A (en) |
ZA (1) | ZA89855B (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991003253A1 (en) * | 1989-09-08 | 1991-03-21 | Fujisawa Pharmaceutical Co., Ltd. | Treatment of insulin-resistant diabetes |
WO1992011865A1 (en) * | 1991-01-11 | 1992-07-23 | Kabi Pharmacia Ab | Use of human igf-i |
WO1993023071A1 (en) * | 1992-05-19 | 1993-11-25 | Kabi Pharmacia Ab | Use of igf-1 |
WO1994009813A1 (en) * | 1992-10-29 | 1994-05-11 | Genentech, Inc. | Method for treatment or prevention of obesity |
EP0642350A1 (en) * | 1993-01-25 | 1995-03-15 | The Beth Israel Hospital Association | Method for modifying, diagnosing, and screening for igf-i sensitive cell barrier properties |
WO1996001124A1 (en) * | 1994-07-04 | 1996-01-18 | Pharmacia & Upjohn Ab | Use of igf-i or analogues thereof in the prevention of diabetes |
US5597797A (en) * | 1990-06-07 | 1997-01-28 | Genentech, Inc. | Method for treatment or prevention of obesity |
WO1998006423A1 (en) * | 1996-08-13 | 1998-02-19 | Genentech, Inc. | Composition comprising insulin and insulin-like growth factor-i (igf-i) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6440928B1 (en) | 1988-12-06 | 2002-08-27 | Colorado State University Research Foundation | Method for treating diabetic neuropathy with NGF |
US5128320A (en) * | 1990-01-18 | 1992-07-07 | Genentech, Inc. | Method of restoring normal growth, weight gain or lean body mass in patients with glucocorticoid excess by administering igf-i |
US5681814A (en) * | 1990-06-07 | 1997-10-28 | Genentech, Inc. | Formulated IGF-I Composition |
JPH06510065A (en) * | 1992-06-08 | 1994-11-10 | カイロン コーポレーション | Uses of growth factors IGF-I and/or IGF-II |
US20070078089A1 (en) * | 1992-07-06 | 2007-04-05 | Ishii Douglas N | Method for effecting changes in the central nervous system by administration of IGF-I or IGF-II |
US5446024A (en) * | 1993-12-17 | 1995-08-29 | Genentech, Inc. | Purification of insulin-like growth factor |
SE9402331D0 (en) * | 1994-07-01 | 1994-07-01 | Pharmacia Ab | New use |
US5728676A (en) * | 1994-09-08 | 1998-03-17 | Ciba-Geigy Corporation | Use of insulin-like growth factors I and II for inhibition of inflammatory response |
US5565428A (en) * | 1995-05-22 | 1996-10-15 | Genentech, Inc. | Method of administration of IGF-I |
US5741776A (en) * | 1995-05-22 | 1998-04-21 | Genentech, Inc. | Method of administration of IGF-I |
EP0766966A3 (en) * | 1995-09-08 | 2001-02-28 | Eli Lilly And Company | Method of treating insulin resistance |
US6015786A (en) * | 1997-02-25 | 2000-01-18 | Celtrix Pharmaceuticals, Inc. | Method for increasing sex steroid levels using IGF or IGF/IGFBP-3 |
US6025368A (en) * | 1997-02-25 | 2000-02-15 | Celtrix Pharmaceuticals, Inc. | Method for treating the symptoms of chronic stress-related disorders using IGF |
US6514937B1 (en) | 1997-02-25 | 2003-02-04 | Celtrix Pharmaceuticals, Inc. | Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3 |
US5916569A (en) * | 1997-03-26 | 1999-06-29 | E. Martin Spencer | Human erectile dysfunction and methods of treatment |
US6121416A (en) | 1997-04-04 | 2000-09-19 | Genentech, Inc. | Insulin-like growth factor agonist molecules |
US6403764B1 (en) * | 1999-01-06 | 2002-06-11 | Genentech, Inc. | Insulin-like growth factor-1 protein variants |
US6420518B1 (en) | 1997-04-04 | 2002-07-16 | Genetech, Inc. | Insulin-like growth factor agonist molecules |
CA2369451C (en) | 1999-04-08 | 2009-09-22 | Genentech, Inc. | Composition based on oppositely-charged polypeptides |
US6040292A (en) * | 1999-06-04 | 2000-03-21 | Celtrix Pharmaceuticals, Inc. | Methods for treating diabetes |
WO2001000223A2 (en) * | 1999-06-25 | 2001-01-04 | Minimed Inc. | Multiple agent diabetes therapy |
WO2001087323A2 (en) | 2000-05-16 | 2001-11-22 | Genentech, Inc. | Method for treating cartilage disorders |
CA2419561A1 (en) * | 2000-08-29 | 2002-03-07 | Colorado State University Research Foundation | Method for treating the central nervous system by administration of igf structural analogs |
JP4489352B2 (en) * | 2001-02-09 | 2010-06-23 | ジェネンテック, インコーポレイテッド | Crystallization of IGF-1 |
WO2002067969A2 (en) | 2001-02-21 | 2002-09-06 | Medtronic Minimed, Inc. | Stabilized insulin formulations |
WO2002072780A2 (en) * | 2001-03-14 | 2002-09-19 | Genentech, Inc. | Igf antagonist peptides |
US6737401B2 (en) | 2001-06-28 | 2004-05-18 | Metronic Minimed, Inc. | Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom |
DE10316583A1 (en) * | 2003-04-10 | 2004-10-28 | B.R.A.H.M.S Aktiengesellschaft | Determination of a mid-regional proadrenomedullin partial peptide in biological fluids for diagnostic purposes, as well as immunoassays for carrying out such a determination |
EP1670413A4 (en) * | 2003-08-21 | 2009-07-08 | Tercica Inc | Method of reducing visceral fat by increasing levels of insulin-like growth factor-i (igf-i) |
ES2788699T3 (en) * | 2004-08-30 | 2020-10-22 | Ipsen Biopharmaceuticals Inc | Procedure and device to diagnose and treat insulin-like growth factor deficiency disorders |
KR102288366B1 (en) * | 2018-03-09 | 2021-08-10 | 경북대학교 산학협력단 | Pharmaceutical composition comprising the extract of Phlomis umbrosa Turczaninow as an effective ingredient for preventing or treating of obesity |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0123228A2 (en) * | 1983-04-25 | 1984-10-31 | Chiron Corporation | Hybrid DNA synthesis of mature insulin-like growth factors |
-
1989
- 1989-01-25 US US07/301,680 patent/US4988675A/en not_active Expired - Lifetime
- 1989-01-26 DE DE8989810074T patent/DE68905205T2/en not_active Expired - Lifetime
- 1989-01-26 EP EP89810074A patent/EP0331630B1/en not_active Expired - Lifetime
- 1989-01-31 PH PH38126A patent/PH26085A/en unknown
- 1989-02-01 AU AU28999/89A patent/AU624595B2/en not_active Expired
- 1989-02-03 IL IL8989166A patent/IL89166A0/en unknown
- 1989-02-03 CA CA000590025A patent/CA1336815C/en not_active Expired - Fee Related
- 1989-02-03 ZA ZA89855A patent/ZA89855B/en unknown
- 1989-02-03 IE IE35789A patent/IE63163B1/en not_active IP Right Cessation
- 1989-02-03 DK DK052189A patent/DK169233B1/en not_active IP Right Cessation
- 1989-02-03 JP JP1024105A patent/JP2831017B2/en not_active Expired - Lifetime
- 1989-02-03 NZ NZ227857A patent/NZ227857A/en unknown
- 1989-02-04 KR KR1019890001312A patent/KR0131087B1/en not_active IP Right Cessation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0123228A2 (en) * | 1983-04-25 | 1984-10-31 | Chiron Corporation | Hybrid DNA synthesis of mature insulin-like growth factors |
Non-Patent Citations (1)
Title |
---|
NATURE, vol. 323, 11th September 1986, pages 169-171; E. SCHEIWILLER et al.: "Growth restoration of insulin-deficient diabetic rats by recombinant human insulin-like growth factor I" * |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991003253A1 (en) * | 1989-09-08 | 1991-03-21 | Fujisawa Pharmaceutical Co., Ltd. | Treatment of insulin-resistant diabetes |
US5674845A (en) * | 1989-09-08 | 1997-10-07 | Fujisawa Pharmaceutical Co., Ltd. | Treatment of insulin-resistant diabetes |
US5597797A (en) * | 1990-06-07 | 1997-01-28 | Genentech, Inc. | Method for treatment or prevention of obesity |
WO1992011865A1 (en) * | 1991-01-11 | 1992-07-23 | Kabi Pharmacia Ab | Use of human igf-i |
EP0501937A1 (en) * | 1991-01-11 | 1992-09-02 | Pharmacia AB (reg.number 556131-9608) | Use of human IGF-I |
AU657729B2 (en) * | 1991-01-11 | 1995-03-23 | Pharmacia Ab | Use of human IGF-I |
US5434134A (en) * | 1991-01-11 | 1995-07-18 | Pharmac Ia Ab | Use of human IGF-1 to treat cardiac disorders |
AU669894B2 (en) * | 1992-05-19 | 1996-06-27 | Novartis Vaccines And Diagnostics, Inc. | Use of IGF-1 |
WO1993023071A1 (en) * | 1992-05-19 | 1993-11-25 | Kabi Pharmacia Ab | Use of igf-1 |
US5466670A (en) * | 1992-05-19 | 1995-11-14 | Pharmacia Ab | Use of IGF-1 |
WO1994009813A1 (en) * | 1992-10-29 | 1994-05-11 | Genentech, Inc. | Method for treatment or prevention of obesity |
EP0642350A1 (en) * | 1993-01-25 | 1995-03-15 | The Beth Israel Hospital Association | Method for modifying, diagnosing, and screening for igf-i sensitive cell barrier properties |
US5612312A (en) * | 1993-01-25 | 1997-03-18 | Moses; Alan C. | Method for treating insulin resistance with IGF-I |
US5637567A (en) * | 1993-01-25 | 1997-06-10 | The Beth Israel Hospital Association | Method for modifying, diagnosing, and screening for IGF-I sensitive cell barrier properties |
EP0642350A4 (en) * | 1993-01-25 | 1995-06-28 | Beth Israel Hospital | Method for modifying, diagnosing, and screening for igf-i sensitive cell barrier properties. |
US5686408A (en) * | 1993-01-25 | 1997-11-11 | The Beth Israel Hospital Association | Method for modifying, diagnosing, and screening for IGF-I sensitive cell barrier properties |
US5736400A (en) * | 1993-01-25 | 1998-04-07 | Moses; Alan C. | Method for modifying, diagnosing and screening for IGF-I sensitive cell barriers |
WO1996001124A1 (en) * | 1994-07-04 | 1996-01-18 | Pharmacia & Upjohn Ab | Use of igf-i or analogues thereof in the prevention of diabetes |
AU689922B2 (en) * | 1994-07-04 | 1998-04-09 | Chiron Corporation | Use of IGF-I or analogues thereof in the prevention of diabetes |
US6342227B1 (en) | 1994-07-04 | 2002-01-29 | Chiron Corporation | Use of IGF-I or analogues thereof in the prevention of diabetes |
WO1998006423A1 (en) * | 1996-08-13 | 1998-02-19 | Genentech, Inc. | Composition comprising insulin and insulin-like growth factor-i (igf-i) |
AU731745B2 (en) * | 1996-08-13 | 2001-04-05 | Genentech Inc. | Composition comprising insulin and insulin-like growth factor-I (IGF-I) |
EP1114644A1 (en) * | 1996-08-13 | 2001-07-11 | Genentech, Inc. | Composition comprising NPH insulin (neutral protamine hagedorn insulin) |
Also Published As
Publication number | Publication date |
---|---|
IE63163B1 (en) | 1995-03-22 |
ZA89855B (en) | 1989-10-25 |
JPH01233227A (en) | 1989-09-19 |
AU2899989A (en) | 1989-08-10 |
NZ227857A (en) | 1992-04-28 |
DE68905205T2 (en) | 1993-07-22 |
EP0331630B1 (en) | 1993-03-10 |
US4988675A (en) | 1991-01-29 |
KR890012667A (en) | 1989-09-18 |
KR0131087B1 (en) | 1998-04-17 |
IE890357L (en) | 1989-08-05 |
DE68905205D1 (en) | 1993-04-15 |
IL89166A0 (en) | 1989-09-10 |
DK52189D0 (en) | 1989-02-03 |
JP2831017B2 (en) | 1998-12-02 |
DK169233B1 (en) | 1994-09-19 |
CA1336815C (en) | 1995-08-29 |
AU624595B2 (en) | 1992-06-18 |
DK52189A (en) | 1989-08-06 |
PH26085A (en) | 1992-02-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4988675A (en) | Method for preventing secondary effects | |
EP0500847B1 (en) | Treatment of obesity with an alpha-2-adrenergic agonist and a growth hormone releasing peptide | |
Clemmons et al. | Reversal of diet-induced catabolism by infusion of recombinant insulin-like growth factor-I in humans | |
EP0327503B1 (en) | Use of igf i in the manufacture of a medicament for the treatment of renal diseases | |
Radosevich et al. | Effects of morphine on glucose homeostasis in the conscious dog. | |
JP2009132682A (en) | Method for administering igf-i | |
US5466670A (en) | Use of IGF-1 | |
US4652548A (en) | Pharmaceutical formulations comprising human insulin, human C-peptide, and human proinsulin | |
AU780400B2 (en) | Methods for treating diabetes | |
US4654324A (en) | Human proinsulin pharmaceutical formulations | |
US4652547A (en) | Pharmaceutical formulations comprising human insulin and human proinsulin | |
AU755897C (en) | Methods of Increasing Sex Hormone Binding Globulin (SHBG) in a Subject | |
Leinsköld et al. | Effect of postoperative insulin‐like growth factor I supplementation on protein metabolism in humans | |
US5948757A (en) | High dose IGF-1 therapy | |
Kovacs et al. | Hypoglycemic effects of insulin-like growth factor-1 in experimental uremia: can concomitant growth hormone administration prevent this effect? | |
HU193522B (en) | Process for producing pharmaceutical preparations containing human proinsulin | |
NZ241617A (en) | Treating and preventing secondary effects of hyperinsulinemia using insulin-like growth factor i (igf i) and lower than normal amounts of insulin | |
IL104777A (en) | Pharmaceutical compositions comprising insulin-like growth factor i | |
Jørgensen et al. | Growth Hormone Effects on Day-to-Day Intermediary Metabolism | |
Clemmons | Growth Hormone and IGF-I as Anabolic Partitioning Hormones |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19890128 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE FR GB IT LI LU NL SE |
|
17Q | First examination report despatched |
Effective date: 19910708 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE FR GB IT LI LU NL SE |
|
REF | Corresponds to: |
Ref document number: 86497 Country of ref document: AT Date of ref document: 19930315 Kind code of ref document: T |
|
REF | Corresponds to: |
Ref document number: 68905205 Country of ref document: DE Date of ref document: 19930415 |
|
ITF | It: translation for a ep patent filed | ||
ET | Fr: translation filed | ||
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
ITTA | It: last paid annual fee | ||
26N | No opposition filed | ||
EPTA | Lu: last paid annual fee | ||
EAL | Se: european patent in force in sweden |
Ref document number: 89810074.8 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PFA Free format text: CIBA-GEIGY AG TRANSFER- NOVARTIS AG |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: 732E |
|
NLS | Nl: assignments of ep-patents |
Owner name: NOVARTIS AG |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: TP |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: IF02 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20080116 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20071219 Year of fee payment: 20 Ref country code: DE Payment date: 20080124 Year of fee payment: 20 Ref country code: SE Payment date: 20080104 Year of fee payment: 20 Ref country code: GB Payment date: 20080123 Year of fee payment: 20 Ref country code: LU Payment date: 20080129 Year of fee payment: 20 Ref country code: IT Payment date: 20080128 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 20080114 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20080108 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20080403 Year of fee payment: 20 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: PE20 Expiry date: 20090125 |
|
EUG | Se: european patent has lapsed | ||
NLV7 | Nl: ceased due to reaching the maximum lifetime of a patent |
Effective date: 20090126 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20090126 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20090125 |